Targeted PI3Kδ inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma

Cancer Biology & Therapy
Tracy C OkoliWilliam D Figg

Abstract

Indolent Non-Hodgkin Lymphomas (iNHL) are typically B-cell malignancies and are incurable with current standard approaches. Thus, there is a demand for novel agents specific for this group of disorders. In a phase II study published by Gopal et al. in the New England Journal of Medicine, idelalisib, a small molecule inhibitor of PI3Kδ that was FDA approved in July of 2014, was shown to be effective when combined with rituximab in patients who cannot tolerate chemotherapy and as last line therapy in patients with iNHL refractory to 2 prior systemic therapies. Idelalisib demonstrated tolerable diarrhea, fatigue, nausea, pyrexia, and cough. While this novel agent is a clinically significant addition to the iNHL arsenal, further research is needed to determine its most appropriate place in iNHL therapy.

References

Sep 24, 2013·Clinical Therapeutics·Alexey V Danilov
Jan 24, 2014·The New England Journal of Medicine·Richard R FurmanSusan M O'Brien
Jan 24, 2014·The New England Journal of Medicine·Ajay K GopalGilles A Salles
Feb 20, 2014·Nature Reviews. Drug Discovery·Ken Garber
May 9, 2014·The Lancet Oncology·Judith A Gilbert
May 31, 2014·Blood·Bruce D Cheson

❮ Previous
Next ❯

Citations

Oct 23, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yan KongJun Guo

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
Yvonne G HewettBinay K Shah
Journal of Clinical and Experimental Hematopathology : JCEH
Ritsuro Suzuki
© 2022 Meta ULC. All rights reserved